Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 1
2009 1
2012 1
2013 3
2014 2
2016 1
2017 1
2018 4
2019 2
2020 6
2021 3
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bellu L, Pambuku A, Farina M, Magni G, Indraccolo S, Gardiman MP, Soffietti R, Zagonel V. Lombardi G, et al. Among authors: lolli i. Lancet Oncol. 2019 Jan;20(1):110-119. doi: 10.1016/S1470-2045(18)30675-2. Epub 2018 Dec 3. Lancet Oncol. 2019. PMID: 30522967 Clinical Trial.
Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
Ricci AD, D'Alessandro R, Rizzo A, Schirizzi A, Vallarelli S, Ostuni C, Troiani L, Lolli IR, Lotesoriere C, Giannelli G. Ricci AD, et al. Among authors: lolli ir. Immunotherapy. 2023 May;15(7):477-486. doi: 10.2217/imt-2022-0301. Epub 2023 Mar 23. Immunotherapy. 2023. PMID: 36950960 Review.
Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues.
Schirizzi A, De Leonardis G, Lorusso V, Donghia R, Rizzo A, Vallarelli S, Ostuni C, Troiani L, Lolli IR, Giannelli G, Ricci AD, D'Alessandro R, Lotesoriere C. Schirizzi A, et al. Among authors: lolli ir. Cancers (Basel). 2023 Apr 19;15(8):2376. doi: 10.3390/cancers15082376. Cancers (Basel). 2023. PMID: 37190304 Free PMC article. Review.
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.
Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, Indraccolo S, Dechecchi MC, Prandini P, Gambari R, Scapoli C, Di Gennaro G, Caccese M, Eoli M, Rudà R, Brandes AA, Ibrahim T, Rizzato S, Lolli I, Lippi G, Delledonne M, Zagonel V, Cabrini G. Santangelo A, et al. Among authors: lolli i. Neuro Oncol. 2021 Feb 25;23(2):264-276. doi: 10.1093/neuonc/noaa156. Neuro Oncol. 2021. PMID: 32661549 Free PMC article.
Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab-Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study.
D'Alessandro R, Refolo MG, Schirizzi A, De Leonardis G, Donghia R, Guerra V, Giannelli G, Lolli IR, Laterza MM, De Vita F, Messa C, Lotesoriere C. D'Alessandro R, et al. Among authors: lolli ir. Front Oncol. 2022 Apr 6;12:862116. doi: 10.3389/fonc.2022.862116. eCollection 2022. Front Oncol. 2022. PMID: 35463372 Free PMC article.
Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab-paclitaxel therapy outcome in advanced gastric cancer: results of prospective study.
D'Alessandro R, Refolo MG, Schirizzi A, De Leonardis G, Donghia R, Guerra V, Giannelli G, Lolli IR, Laterza MM, De Vita F, Messa C, Lotesoriere C. D'Alessandro R, et al. Among authors: lolli ir. Front Oncol. 2023 Apr 14;13:1187014. doi: 10.3389/fonc.2023.1187014. eCollection 2023. Front Oncol. 2023. PMID: 37124498 Free PMC article.
31 results